FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
1-Year Return
52.94%
This Quarter Return
+10.82%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.5B
AUM Growth
+$313M
(+14%)
Cap. Flow
+$160M
Cap. Flow
% of AUM
6.41%
Top 10 Holdings %
Top 10 Hldgs %
67.82%
Holding
55
New
8
Increased
16
Reduced
5
Closed
6
Top Buys
| 1 |
Zai Lab
ZLAB
|
$33.5M |
| 2 |
Aura Biosciences
AURA
|
$31.9M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
$22.6M |
| 4 |
Evolus
EOLS
|
$22.4M |
| 5 |
Akero Therapeutics
AKRO
|
$19.6M |
Top Sells
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$36M |
| 2 |
Soleno Therapeutics
SLNO
|
$35.7M |
| 3 |
Merus
MRUS
|
$15.7M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$7.81M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$7.2M |
Sector Composition
| 1 | Healthcare | 99.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
CG Oncology
CGON
$2.24B
| $20M | 0.8% |
770,000
| – | – |
|
|
27
Akero Therapeutics
AKRO
$3.49B
| $19.6M | 0.78% |
+366,784
| New | +$19.6M |
|
28
Cytokinetics
CYTK
$5.93B
| $18.3M | 0.73% |
+554,731
| New | +$18.3M |
|
29
Lexeo Therapeutics
LXEO
$268M
| $17.8M | 0.71% |
4,424,725
+3,469,210
| +363% | +$13.9M |
|
30
Avidity Biosciences
RNA
$6.13B
| $17.8M | 0.71% |
625,000
+100,000
| +19% | +$2.84M |
|
|
JBIO
31
Jade Biosciences, Inc. Common Stock
JBIO
$246M
| $17.7M | 0.71% |
+1,772,116
| New | +$17.7M |
|
|
PVLA
32
Palvella Therapeutics, Inc. Common Stock
PVLA
$582M
| $16.3M | 0.65% |
722,400
+32,388
| +5% | +$730K |
|
33
Vaxcyte
PCVX
$4.06B
| $15.4M | 0.62% |
474,405
-65,000
| -12% | -$2.11M |
|
34
Travere Therapeutics
TVTX
$1.82B
| $14.8M | 0.59% |
+1,002,092
| New | +$14.8M |
|
35
Dyne Therapeutics
DYN
$1.86B
| $14.3M | 0.57% |
1,505,984
+62,643
| +4% | +$596K |
|
36
Cogent Biosciences
COGT
$1.8B
| $12.5M | 0.5% |
1,734,601
+798,025
| +85% | +$5.73M |
|
37
Immunocore
IMCR
$1.79B
| $12.1M | 0.48% |
384,782
+83,612
| +28% | +$2.62M |
|
38
Oric Pharmaceuticals
ORIC
$1.03B
| $10.8M | 0.43% |
1,065,334
-344,859
| -24% | -$3.5M |
|
|
AUTL
39
Autolus Therapeutics
AUTL
$381M
| $10.5M | 0.42% |
4,623,324
| – | – |
|
|
VALN
40
Valneva
VALN
$755M
| $8.24M | 0.33% |
+1,458,333
| New | +$8.24M |
|
|
CBIO
41
Crescent Biopharma, Inc. Common Stock
CBIO
$185M
| $7.32M | 0.29% |
+453,685
| New | +$7.32M |
|
42
Design Therapeutics
DSGN
$341M
| $6.58M | 0.26% |
1,953,547
| – | – |
|
|
ORKA
43
Oruka Therapeutics, Inc. Common Stock
ORKA
$561M
| $6.54M | 0.26% |
583,327
| – | – |
|
|
SLN
44
Silence Therapeutics
SLN
$250M
| $5.63M | 0.23% |
970,130
-178,461
| -16% | -$1.04M |
|
45
Allogene Therapeutics
ALLO
$240M
| $4.37M | 0.17% |
3,868,750
| – | – |
|
46
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$59.9M
| $4M | 0.16% |
500,333
| – | – |
|
47
MacroGenics
MGNX
$125M
| $3.84M | 0.15% |
3,175,665
| – | – |
|
48
Adverum Biotechnologies
ADVM
$66.1M
| $2.3M | 0.09% |
1,069,244
| – | – |
|
|
ELEV
49
DELISTED
Elevation Oncology
ELEV
| $2.2M | 0.09% |
5,993,579
| – | – |
|
|
50
Acadia Pharmaceuticals
ACAD
$4.32B
| – | – |
-470,338
| Closed | -$7.81M |
|